Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Florence – page 35

805 clinical trials in Florence, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Florence at a glance
805
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

805 trials in Florence

Open in trial search

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Servier Affaires Medicales

IgA nephropathy

Not yet recruiting

Study on Corticosteroids, Dapagliflozin, and Drug Combination for Proteinuria in IgA Nephropathy Patients with Active or Chronic Kidney Lesions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Fondazione Schena Centro Europeo Della Ricerca Sulle Malattie Renali

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Psoriasis

Not recruiting

Study of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.

Hidradenitis

Not recruiting

Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Migraine

Not recruiting

Study of Rimegepant for Prevention of Menstrual Migraine in Women Aged 18-45 Years

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Obesity+1

Not recruiting

Study on the Effectiveness and Safety of Maridebart Cafraglutide for Adults with Obesity or Overweight Without Type 2 Diabetes

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Study on Itepekimab for Adults with Chronic Rhinosinusitis and Nasal Polyps

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Florence

What the registry says about research in the country

01 Neurological Disorders

Clinical research focusing on innovative treatments for frontotemporal dementia, multiple sclerosis, and Dravet syndrome. Studies evaluate novel therapeutic approaches including DNL593 for FTD and frexalimab for relapsing MS.

  • Frontotemporal Dementia Treatment
  • Multiple Sclerosis Management
  • Seizure Control in Dravet Syndrome

Emphasis on safety assessment and long-term efficacy monitoring.

02 Oncology Research

Comprehensive studies targeting various cancer types including colorectal cancer, breast cancer, and lung cancer. Trials explore combination therapies and novel treatment approaches.

  • Metastatic Colorectal Cancer Treatment
  • Advanced Breast Cancer Therapies
  • NSCLC Post-Surgery Care

Focus on targeted therapies and personalized treatment approaches.

03 Autoimmune Conditions

Investigating treatments for psoriatic arthritis, Sjögren's syndrome, and systemic sclerosis. Research includes evaluation of new biologics and targeted therapies.

  • Psoriatic Arthritis Management
  • Sjögren's Syndrome Treatment
  • Systemic Sclerosis Interventions

Studies aim to improve quality of life and disease management.

04 Respiratory Medicine

Studies examining treatments for COPD and respiratory infections, including evaluation of tezepelumab for moderate to severe COPD and prevention of RSV in infants.

  • COPD Exacerbation Management
  • RSV Prevention in Infants
  • Respiratory Disease Therapies

Focus on improving respiratory outcomes and prevention strategies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.